COMMUNIQUÉS West-GlobeNewswire

Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
03/02/2026
Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13th Annual MedTech, [...]
Eleusis to Debut as the World’s First Legal Luxury Psychedelic Immersion
03/02/2026
ST VINCENT AND THE GRENADINES, Caribbean, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Eleusis , the world’s first legal luxury psychedelic immersion, using DMTx protocols, will officially debut in March 2026 on the island of [...]
Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems
03/02/2026
This clearance enables the next phase of development aimed ultimately at removing the adjunct use in the US The newly cleared capability provides radiologists with a 2D image generated directly from the tomosynthesis [...]
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
03/02/2026
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase price NEW YORK and VIENNA, Austria, Feb. 03, 2026 (GLOBE NEWSWIRE [...]
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
03/02/2026
PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold ® (migalastat) in Fabry disease and [...]
Byonyks X1: Revolutinizing Dialysis - Now FDA Cleared and Planning to start Patients in the U.S.
03/02/2026
A major regulatory milestone positioning Byonyks as a new entrant in home-based renal care CHICAGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Byonyks, headquartered in Chicago, Illinois, has received U.S. FDA 510(k) clearance [...]
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
03/02/2026
This is the first time MEAI, Clearmind’s next-generation, non-hallucinogenic neuroplastogen, has been named in U.S. federal legislation Vancouver, Canada, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( [...]
MedRisk Acquires Horizon Casualty Services
03/02/2026
Strengthens MedRisk’s ability to deliver better outcomes and an elevated experience WEST CONSHOHOCKEN, Pa., Feb. 03, 2026 (GLOBE NEWSWIRE) -- MedRisk, a leading provider of managed care solutions for the workers’ [...]
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products
03/02/2026
-- Multi-Product Distribution Agreement Marks Continued Commercial Momentum in Europe -- ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non- [...]
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
03/02/2026
April 10, 2026 Target Action Date for RP1 in Advanced Melanoma WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of [...]
SRx Health Solutions Significantly Reduces Short Position of Cryptocurrency Portfolio Amidst Current Market Volatility
03/02/2026
NORTH PALM BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced it has significantly reduced its short position across its cryptocurrency [...]
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/02/2026
MONTREAL and CHARLOTTE, N.C., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a [...]
AdhereHealth Announces Appointment of CEO Kempton Presley and President & COO Patrick McNulty as Members of the Board of Directors
03/02/2026
NASHVILLE, Tenn., Feb. 03, 2026 (GLOBE NEWSWIRE) -- AdhereHealth today announced the appointment of Kempton Presley, Chief Executive Officer, and Patrick “Pat” McNulty, President and Chief Operating Officer, as members [...]
Ardelyx Receives New Patent for Tenapanor
03/02/2026
New patent covers IBSRELA® and XPHOZAH® and expires in 2042 WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and [...]
HFMA’s Vitalic Health to gather more than 50 payers, providers and tech leaders to address rising claim denials
03/02/2026
CHICAGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association’s Vitalic Health announced today it will convene more than 50 payers, providers and tech companies to simplify and standardize [...]
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
03/02/2026
Company highlights accelerating access and revenue growth for ARBLI ™ and confirms REZENOPY ™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million Outlines Q1 2026 [...]
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
03/02/2026
Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug candidate PLX-200 [...]
Vivos Inc Updates Human Therapy Progress in India
03/02/2026
Kennewick, WA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to provide shareholders with a positive update on the ongoing human therapy demonstrations in India using RadioGel ® Precision [...]
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
03/02/2026
BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today [...]

Pages